This technology is a pharmaceutical composition for cancer prevention and treatment, featuring a novel anticancer peptide consisting of 7–10 amino acids, with the amino acid sequence of SEQ ID NO: 4 as its core. The peptide is either SEQ ID NO: 4 itself or a form with Y, YF, or YFR added to its C-terminus, and it can also be formulated as a health functional food or anticancer adjuvant.
Conventional cytotoxic anticancer drugs attack normal cells, causing systemic toxicity and various side effects. Monoclonal antibody targeted therapies like cetuximab, trastuzumab, and bevacizumab, developed to overcome these issues, have limited efficacy in patients with mutations in downstream signaling genes. Consequently, there is a persistent demand for cancer treatments with novel mechanisms of action.
This technology utilizes a peptide containing the sequence of SEQ ID NO: 2, which has been shown to inhibit cancer cell proliferation and metastasis, induce apoptosis, and improve drug resistance. It is specifically designed to be used as an adjuvant for cancers that have developed resistance to chemotherapy, focusing on restoring the efficacy of existing treatments. Applicable to solid tumor treatments (e.g., lung, colon, breast cancer), combination adjuvants for resistant patients, and health functional food ingredients, these short peptides are easy to synthesize and modify, expanding treatment options for resistant cancers that do not respond to targeted antibodies.
CN117897393A, EP4365187A1, US2024-0293500A1, WO2023-277514A1
